E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines (Q46197811)

20 December 2017

title

E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines (English)

1 reference

20 December 2017

author name string

M Kitagawa

1

1 reference

20 December 2017

M Aonuma

2

1 reference

20 December 2017

S H Lee

3

1 reference

20 December 2017

S Fukutake

4

1 reference

20 December 2017

F McCormick

5

1 reference

20 December 2017

language of work or name

English

0 references

publication date

2 June 2008

1 reference

20 December 2017

published in

Oncogene

1 reference

20 December 2017

volume

27

1 reference

20 December 2017

issue

40

1 reference

20 December 2017

page(s)

5303-5314

1 reference

20 December 2017

https://scigraph.springernature.com/pub.10.1038/onc.2008.164

exact match

0 references

cites work

Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.164

p14ARF links the tumour suppressors RB and p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.164

MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.164

The regulation of E2F by pRB-family proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.164

E2F-1-induced p53-independent apoptosis in transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.164

Role for the p53 homologue p73 in E2F-1-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.164

MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.164

HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.164

Inactivation of the p53 pathway in retinoblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.164

p53-dependent apoptosis modulates the cytotoxicity of anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.164

The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.164

E1A is sufficient by itself to induce apoptosis independent of p53 and other adenoviral gene products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.164

Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.164

Selective induction of p53 and chemosensitivity in RB-deficient cells by E1A mutants unable to bind the RB-related proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.164

Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.164

siRNA-mediated gene silencing: a global genome view

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.164

Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.164

E2F1-induced apoptosis: turning killers into therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.164

Role of the p53-homologue p73 in E2F1-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.164

Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.164

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.164

Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.164

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.164

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.164

Live or let die: the cell's response to p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.164

Hdmx modulates the outcome of p53 activation in human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.164

Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.164

Levels of HdmX Expression Dictate the Sensitivity of Normal and Transformed Cells to Nutlin-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.164

Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2008.164

31 March 2020

Identifiers

DOI

10.1038/ONC.2008.164

1 reference

20 December 2017

PubMed ID

18521084

1 reference

20 December 2017